Rajinder S Sawhney

Summary

Affiliation: University at Buffalo
Country: USA

Publications

  1. doi request reprint A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling
    Rajinder S Sawhney
    Department of Pharmacology and Toxicology, SUNY at Buffalo, Buffalo, New York, USA
    J Cell Physiol 219:152-61. 2009
  2. ncbi request reprint Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 281:8497-510. 2006
  3. ncbi request reprint Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 279:47379-90. 2004
  4. ncbi request reprint Integrin alpha2 and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-alpha-driven colon cancer cells
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 278:19861-9. 2003
  5. ncbi request reprint Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 277:75-86. 2002

Detail Information

Publications5

  1. doi request reprint A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling
    Rajinder S Sawhney
    Department of Pharmacology and Toxicology, SUNY at Buffalo, Buffalo, New York, USA
    J Cell Physiol 219:152-61. 2009
    ..Using different cancer cells, our experiments unveil a novel mechanism by which VN receptors and FAK could promote cancer metastasis via ERK5 activation...
  2. ncbi request reprint Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 281:8497-510. 2006
    ..The data suggest that blocking the integrin alpha2/FAK/ERK/mu-calpain pathway may be an important strategy to reduce cancer progression...
  3. ncbi request reprint Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 279:47379-90. 2004
    ..These experiments show for the first time that autocrine TGFalpha regulates cell adhesion function by multiple signaling pathways via specific phosphorylation sites of S6K in cancer cells...
  4. ncbi request reprint Integrin alpha2 and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-alpha-driven colon cancer cells
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 278:19861-9. 2003
    ..Thus, this study implicates ERK/MAPK signaling activated by endogenous TGF-alpha as one of the mechanistic features controlling metastatic spread...
  5. ncbi request reprint Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands
    Rajinder S Sawhney
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 277:75-86. 2002
    ....